Canaccord Genuity initiated coverage of ShockWave Medical (NASDAQ:SWAV) with a “buy” rating and $39 price target. The stock closed at $33.47 on March 29. Analyst Jason Mills writes that ShockWave’s technology –...

Maxim Group downgraded Proteon Therapeutics (NASDAQ:PRTO) to “hold” from “buy” and withdrew its previous $5 price target after the company’s second Phase 3 study of vonapanitase failed to reach statistical significance...

EyePoint Pharmaceuticals (NASDAQ:EYPT) priced a public offering of 10,526,500 of its common shares at a price of $1.90 each to raise about $20-million. EyePoint also granted underwriters a 30-day option to purchase up...

SVB Leerink launched coverage of Fate Therapeutics (NASDAQ:FATE) with an “outperform” rating and $20 price target. The stock closed at $16.71 on March 27. Analyst Daina Graybosch writes that Fate is at the forefront of...

SVB Leerink initiated coverage of Affimed NV (NASDAQ:AFMD) with an “outperform” rating and $8 price target. The stock closed at $4.17 on March 27. “Our positive view is fuelled by the potential of the company’s novel...

Maxim Group raised its price target for Atossa Genetics (NASDAQ:ATOS) to $9 from $5 after the Institutional Review Board approved the use of oral endoxifen as a post-mastectomy treatment in pre-menopausal, estrogen...

Roth Capital Partners downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “neutral” with a price target of $1.70 after the company’s ENCORE-NF trial failed to meet its primary endpoint of an improvement of fibrosis...

Roth Capital Partners downgraded Recro Pharma (NASDAQ:REPH) to “neutral” with a price target of $7.50 after the company received a second complete response letter (CRL) from the FDA about its NDA for meloxicam, an...

Canaccord Genuity raised its price target for Nevro (NYSE:NVRO) to $62 from $46 after the medical device maker appointed Keith Grossman as president and CEO, effective immediately. The stock closed at $44.77 on March 19...

Analysts for William Blair and Roth Capital Partners downgraded Restoration Robotics (NASDAQ:HAIR) after the company said it is merging with closely-held Venus Concept. The stock was quoted at 81 cents, down 9 cents, at...

BTIG launched coverage of Momenta Pharmaceuticals (NASDAQ:MNTA) with a “neutral” rating. The stock closed at $14.15 on March 15. Analyst Thomas Schrader writes that Momenta’s transition from a generics company to a more...

Roth Capital Partners initiated coverage of InMed Pharmaceuticals (TSX:IN; OTCQX:IMLFF) with a “buy” rating and 12-month price target of $1.10. The stock closed at 57 cents on March 15. InMed is focused on developing...

BTIG initiated coverage of Arcus Biosciences (NYSE:RCUS) with a “buy” rating and $20 price target. The stock closed at $11.67 on March 15. Arcus is focused on driving antitumor immune responses beyond the level...

BTIG launched coverage of Fluidigm (NASDAQ:FLDM) with a “buy” rating and price target of $15. The stock closed at $12.79 on March 13. Analyst Sung Ji Nam writes that the long-term growth or market potential for the...

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $27 from $22 after the company’s fourth quarter results beat expectations. The stock closed at $19.85 on March 12. The company, which develops non...

BTIG raised its price target for Senseonics (NYSE American:SENS) to $4 from $3, saying the company’s new Patient Access Bridge program makes strategic sense, even though it caused Senseonics to lower its 2019 guidance...

H.C. Wainwright lowered its price target for Trillium Therapeutics (NASDAQ:TRIL) to $4 from $10, citing dilution from a $15-million financing on March 8. The stock closed at 67 cents on March 11. Analyst Swayampakula...

SVB Leerink analyst Dr. Pasha Sarraf assumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a 12-month price target of $22. The stock closed at $12.36 on March 8. Dr. Sarraf writes that...

SVB Leerink initiated coverage of Avedro (NASDAQ:AVDR) with an “outperform” rating and $20 price target. The stock closed at $11.70 on March 8. Analyst Danielle Antalffy writes that the company’s key growth driver is...

SVB Leerink downgraded American Renal Associates (NYSE:ARA) to “market perform” from “outperform” and lowered its price target to $14 from $22 after the company delayed filing its 10-K and reporting fourth quarter...